hrvatski

Azithromycin in the treatment of chronic bacterial prostatitis

Chronic bacterial prostatitis can be caused by "traditional uropathogens" such as Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae and Pseudomonas aeruginosa, or by "unusual", "non-traditional uropathogens" like Chlamydia trachomatis, Ureaplasma urealyticum, staphylococci or others, and is also a biofilm disease. A total of 307 patients with chronic prostatitis caused by Chlamydia trachomatis were treated with azithromycin in a total dose of 4.0, 4.5 or 6.0 g for 3-4 weeks. Eradication of Chlamydia trachomatis was achieved in about 80%, with 70% of patients clinically cured. There were no statistically significant differences between these 3 dosage regimens. A total of 82 patients with chronic prostatitis caused by Ureaplasma urealyticum were treated with azithromycin in a total dose of 4.5 g for 3 weeks. The eradication of Ureaplasma urealyticum was 85% and clinical cure 76%. Azithromycin proved to be an effective and safe antimicrobial drug for the treatment of chronic prostatitis caused by Chlamydia trachomatis or Ureaplasma urealyticum. It is recommended in a total dose of 4.5 g po. during 3 weeks, administered for 3 days weekly in a dose 1 x 500 mg po. per day. A total of 29 patients with chronic prostatitis caused by traditional uropathogens were treated orally with ciprofloxacin 500 mg b.i.d. for 28 days. 31 patient was treated with a combination of ciprofloxacin 500 mg b.i.d. for 28 days, with azithromycin 500 mg once a day, during the first three consecutive days of each week of treatment with ciprofloxacin. A significantly higher eradication and clinical cure rate was achieved in the group of patients treated with a combination of ciprofloxacin and azithromycin than in the ciprofloxacin group. The results of this research of the efficacy and tolerability of azithromycin in the treatment of chronic bacterial prostatitis caused by traditional and unusual pathogens are an additional confirmation that a significant improvement has been achieved in the clinical use of azithromycin for the treatment of urogenital and sexually transmitted infections.

Azithromycin; treatment; chronic bacterial prostatitis

nije evidentirano